Procarbazine hydrochloride
| Code | Size | Price |
|---|
| TAR-T1488-100mg | 100mg | £103.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T1488-1mL | 1 mL * 10 mM (in DMSO) | £107.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T1488-200mg | 200mg | £121.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Procarbazine Hydrochloride is the hydrochloride salt of a methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.
CAS:
366-70-1
Formula:
C12H20ClN3O
Molecular Weight:
257.76
Pathway:
Cell Cycle/Checkpoint; DNA Damage/DNA Repair
Purity:
0.98
SMILES:
Cl.CNNCc1ccc(cc1)C(=O)NC(C)C
Target:
DNA Alkylator/Crosslinker; DNA/RNA Synthesis
References
1. Ogawa K, et al. Mutat Res,2003, 539(1-2), 145-155.
2. Suzuki T, et al. Mutat Res,1999, 444(2), 269-281.
3. Weissenberg R, et al. Arch Androl,2002, 48(2), 91-100.
4. Holt A, et al. J Pharm Pharmacol,1995, 47(10), 837-845.
5. Pletsa V, et al. Carcinogenesis,1997, 18(11), 2191-2196.